|
||
| |||||||
Hitchin, UK, 1 September 2005 York Pharma, the AIM-listed (AIM:YRK) strategic acquirer, developer and marketer of pharmaceutical products in the field of dermatology, announces the appointment of a Sales & Marketing Director, Neil Symmonds, who will join York Pharma’s UK operating company on 1st September 2005. York Pharma (UK) Limited will operate out of offices in Central Milton Keynes in Buckinghamshire effective 1st September 2005. Mr Neil Symmonds, 37, a graduate of Plymouth University, has extensive experience in the pharmaceutical industry, and specifically within dermatology. He has direct sales experience gained at Astra and Sandoz, where he also became a product manager for the Lamisil® brand - the largest selling antifungal worldwide. Following the Sandoz/Ciba-Geigy merger he took over the marketing of Neoral® for Novartis (UK). He joined Galderma (UK) Limited in 1998 as product manager, where he handled the re-launch of Loceryl® an antifungal acquired from Roche; and was involved in its international commercial strategy. He was promoted to marketing manager in 2000, and held responsibility for public affairs from 2003. Since then he has also held positions as the industry representative on committees interfacing with the department of health in relation to the modernisation of dermatology services. Terry Sadler, CEO of York Pharma, said “Following the filing with the MHRA of our lead product, the novel antifungal Abasol™ last month, we are now laying the foundations for our UK commercial operations with the appointment of Neil Symmonds and the establishment of our UK operating company in Milton Keynes. Neil’s past experience will be invaluable to us as we plan the UK and International commercialisation of Abasol™. We are delighted to have him join us to spearhead our first launch of Abasol™ and to build our UK dermatological franchise” --ENDS-- For more information please contact:
Notes to editors: About York Pharma plc York Pharma is an AIM-listed strategic acquirer, developer and marketer of pharmaceutical products in the field of dermatology. Its portfolio now embraces skin diseases that make up more than 70% of the global $10bn dermatology market, and its lead product, Abasol for the treatment of fungal infections of the skin, has been filed for European marketing approval. For further information, please go to www.yorkpharma.com
|
| |||||||||||||||||||
| ||||||||
